Biography
Dr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.
Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.
Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.
He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.
Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.
Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.
He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.
When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach.
Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.
Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.
He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.
Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.
Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.
He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.
When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification, American Board of Internal Medicine, Hematology
- Board Certification, American Board of Internal Medicine, Medical Oncology
- Fellowship, Temple University Cancer Center, Hematology and Oncology
-
- Post-Doctoral Fellowship, Temple University, Fox Chase Cancer Center
- Residency, University of Massachusetts, Internal Medicine
- Medical Degree, Punjab Medical College, Faisalabad, Pakistan
Publications
-
A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
Rischin, D., Boyer, M. J., Brzezniak, C. E., Colevas, A. D., Doebele, R. C., Gilbert, J., … Liu, S. V. (2016). A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Bendell, J., Sharma, S., Patel, M. R., Windsor, K. S., Wainberg, Z. A., Gordon, M., … Starodub, A. (2020). Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. The Oncologist. -
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.
Dittrich, C., Kosty, M., Jezdic, S., Pyle, D., Berardi, R., Bergh, J., … Yarden, Y. (2016). ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 1(5), e000097. -
-
Survivin expression and impact on head and neck cancer outcomes.
Khan, S. A., Burke, M., Zhu, F., Yang, D.-H., Dubyk, C., Mehra, R., … Burtness, B. (2020). Survivin expression and impact on head and neck cancer outcomes. Oral Oncology, 112, 105049. -
Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers.
Palsgrove, D., Allahabadi, S., & Khan, S. A. (2021). Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers. Surgical Pathology Clinics, 14(1), 151–63. -
Extracapsular extension, pathologic node status, and adjuvant treatment in primary surgery patients with human papillomavirus-mediated oropharyngeal cancer: A national hospital-based retrospective cohort analysis.
Day, A. T., Yang, A. M., Tanamal, P., Blackwell, J.-M., Wang, E., Sumer, B. D., … Sher, D. J. (2021). Extracapsular extension, pathologic node status, and adjuvant treatment in primary surgery patients with human papillomavirus-mediated oropharyngeal cancer: A national hospital-based retrospective cohort analysis. Head & Neck. -
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Ahmed, M., von Itzstein, M. S., Sheffield, T., Khan, S., Fattah, F., Park, J. Y., … Gerber, D. E. (2021). Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(6). -
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)
Khan, S., Sun, Z., Pillai, R., Dahlberg, S., Malhotra, J., Keresztes, R., … Ramalingam, S. (2021). Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Risk factors for ED visits and admissions during outpatient chemotherapy in head and neck cancer
Shukla, N., Saraswathula, A., Khan, S. A., & Divi, V. (2021). Risk factors for ED visits and admissions during outpatient chemotherapy in head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.
Lai, S. Y., Torres-Saavedra, P. A., Dunlap, N. E., Beadle, B. M., Chang, S. S., Subramaniam, R. M., … Le, Q.-T. (2021). NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma.
Abdalla, A. S., Sheybani, N. D., & Khan, S. A. (2022). Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma. PET Clinics. -
Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks
Day, A. T., Sher, D. J., Lee, R. C., Truelson, J. M., Myers, L. L., Sumer, B. D., … Gordin, E. A. (2020). Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. ORAL ONCOLOGY, 105, 104684. -
Association of electronic medical record (EMR) QTc alerts with higher mortality within 10 days for patients with blood, lung, GI, and soft tissue cancer.
Bleiberg, B. A., Xie, D., Lightfoot, T., Reisch, J., & Khan, S. A. (2019). Association of electronic medical record (EMR) QTc alerts with higher mortality within 10 days for patients with blood, lung, GI, and soft tissue cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon
Khan, S., von Itzstein, M. S., Lu, R., Bermas, B. L., Karp, D. R., Khan, S. A., … Gerber, D. E. (2020). Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon. ONCOLOGIST, 25(5), E753–E757. -
Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors
Melear, J., Lakhani, N., O'Shaughnessy, J. A., Wilks, S. T., Khan, S., Chandana, S. R., … Burtness, B. (2019). Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors. MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH. -
Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer
Sacks, R., Law, J. Y., Zhu, H., Beg, M. S., Gerber, D. E., Sumer, B. D., … Khan, S. A. (2020). Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer. ONCOLOGY, 98(3), 179–185. -
Therapy with tyrosine kinase inhibitor lenvatinib in radioactive iodine-naive advanced differentiated thyroid cancer
Sukumar, J. S., Moore, W., & Khan, S. A. (2019). Therapy with tyrosine kinase inhibitor lenvatinib in radioactive iodine-naive advanced differentiated thyroid cancer. INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 6(4). -
Head and neck neuroendocrine tumors at a single institution over 15 years
Bacalao, M., Beg, M. S., Cavuoti, D., Zhu, H., Sumer, B., Myers, L., … Khan, S. A. (2019). Head and neck neuroendocrine tumors at a single institution over 15 years. CLINICAL CASE REPORTS, 7(12), 2508–2512. -
Evaluating sociodemographic, behavioral and psychologic disparities in 918 head and neck cancer survivors.
Day, A. T., Vasudevan, A., Wynings, E., Balachandra, S., Khan, S. A., Sumer, B. D., & Murphy, C. C. (2019). Evaluating sociodemographic, behavioral and psychologic disparities in 918 head and neck cancer survivors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Confluent tracheal recurrences of head and neck squamous cell carcinoma
Bleiberg, B. A., Abu-Hijleh, M., Moore, W., & Khan, S. A. (2019). Confluent tracheal recurrences of head and neck squamous cell carcinoma. CLINICAL CASE REPORTS, 7(10), 1849–1853. -
Prevalence and usage patterns of opiates in patients with lung, breast, and head and neck cancer.
Westbrook, K. A., Ahn, C., & Khan, S. A. (2018). Prevalence and usage patterns of opiates in patients with lung, breast, and head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Montesion, M., Chung, C. H., Sokol, E. S., Khan, S. A., Kang, H., Albacker, L. A., … Ali, S. M. (2018). Pan-squamous genomic profiling stratified by anatomic tumor site and viral association. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS. -
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
Khan, S. A., Ci, B., Xie, Y., Gerber, D. E., Beg, M. S., Sherman, S. I., … Ali, S. M. (2019). Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 41(6), 1928–1934. -
Association between treatment delays and oncologic outcome in patients treated with surgery and radiotherapy for head and neck cancer
Tumati, V., Hoang, L., Sumer, B. D., Truelson, J. M., Myers, L. L., Khan, S., … Sher, D. J. (2019). Association between treatment delays and oncologic outcome in patients treated with surgery and radiotherapy for head and neck cancer. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 41(2), 315–321. -
Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer
Singh, J., Moore, W., Fattah, F., Jiang, X., Zheng, J., Kurian, P., … Khan, S. A. (2019). Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 41(1), E11–E15. -
Comparative effectiveness of primary radiotherapy versus surgery in elderly patients with locally advanced oropharyngeal squamous cell carcinoma
Sher, D. J., Yan, J., Day, A., Sumer, B. D., Nhat-Long Pham, Khan, S., & Zhu, H. (2019). Comparative effectiveness of primary radiotherapy versus surgery in elderly patients with locally advanced oropharyngeal squamous cell carcinoma. ORAL ONCOLOGY, 88, 18–26. -
Risk of Unplanned Hospital Encounters in Patients Treated With Radiotherapy for Head and Neck Squamous Cell Carcinoma
Moore, Z. R., Nhat-Long Pham, Shah, J. L., Nedzi, L., Sumer, B. D., Day, A. T., … Sher, D. J. (2019). Risk of Unplanned Hospital Encounters in Patients Treated With Radiotherapy for Head and Neck Squamous Cell Carcinoma. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 57(4), 738-+. -
Immune dysregulation in cancer patients developing immune-related adverse events
Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J., Gloria-McCutchen, Y., … Gerber, D. E. (2019). Immune dysregulation in cancer patients developing immune-related adverse events. BRITISH JOURNAL OF CANCER, 120(1), 63–68. -
Blocking the DC-HIL receptor reverses the T-cell suppression induced by proliferating myeloid-derived suppressor cells in common cancer types
Kobayashi, M., Chung, J.-S., Beg, M., Arriaga, Y., Verma, U., Courtney, K., … Ariizumi, K. (2017). Blocking the DC-HIL receptor reverses the T-cell suppression induced by proliferating myeloid-derived suppressor cells in common cancer types. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Comprehensive genomic profiling of anaplastic thyroid carcinoma
Bowles, D. W., Ross, J. S., Gay, L. M., Agrawal, V., Ali, S. M., & Khan, S. A. (2018). Comprehensive genomic profiling of anaplastic thyroid carcinoma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Underlying host immune dysregulation in cancer patients developing immune-related adverse events.
Gerber, D. E., Khan, S., Luo, X., Khan, S. A., Fattah, F., Saltarski, J., … Wakeland, E. (2018). Underlying host immune dysregulation in cancer patients developing immune-related adverse events. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy
Khan, S. A., Kurian, P., Mobley, B., Burks, T., Beg, M. S., Ross, J. S., … Bowles, D. W. (2018). Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Racial and gender disparities in therapy and outcomes of squamous cell cancer of the anus
Gupta, A., Arora, N., Zhu, H., Christie, A., Meyer, J. J., Khan, S. A., & Beg, M. S. (2017). Racial and gender disparities in therapy and outcomes of squamous cell cancer of the anus. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients
Li, J. J., Harper, J., Bhulani, N., Gerber, D. E., Khan, S. A., Madrigales, A., … Beg, M. S. (2017). Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients
Kobayashi, M., Chung, J.-S., Beg, M., Arriaga, Y., Verma, U., Courtney, K., … Ariizumi, K. (2019). Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients. CLINICAL CANCER RESEARCH, 25(2), 828–838. -
Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis
Beg, M. S., Gupta, A., Sher, D., Ali, S., Khan, S., Gao, A., … Mortensen, E. M. (2018). Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 41(8), 766–771. -
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy
Mohamad, O., de Leon, A. D., Schroeder, S., Leiker, A., Christie, A., Zhang-Velten, E., … Hannan, R. (2018). Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. ONCOIMMUNOLOGY, 7(7), e1440168. -
How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis
Khan, S. A., Pruitt, S. L., Xuan, L., Makris, U., & Gerber, D. E. (2018). How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. LUNG CANCER, 115, 97–102. -
Risk of contralateral nodal failure following ipsilateral IMRT for node-positive tonsillar cancer
Gottumukkala, S., Nhat-Long Pham, Sumer, B., Myers, L., Truelson, J., Nedzi, L., … Sher, D. J. (2017). Risk of contralateral nodal failure following ipsilateral IMRT for node-positive tonsillar cancer. ORAL ONCOLOGY, 75, 35–38. -
Genomic profiling of squamous malignancies across anatomic sites.
Chung, C. H., Frampton, G. M., Chalmers, Z. R., Chung, J., Khan, S. A., Schrock, A. B., … Ganesan, S. (2017). Genomic profiling of squamous malignancies across anatomic sites. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.
Khan, S. A., Puligandla, M., Dahlberg, S. E., Masters, G. A., Langer, C. J., Brahmer, J. R., … Ramalingam, S. S. (2017). Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Comparative effectiveness of primary radiotherapy versus surgery in oropharyngeal squamous cell carcinoma in elderly patients: A SEER-Medicare analysis.
Sher, D. J., Yan, J., Strom, T. J., Khan, S. A., & Zhu, H. (2017). Comparative effectiveness of primary radiotherapy versus surgery in oropharyngeal squamous cell carcinoma in elderly patients: A SEER-Medicare analysis. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
In-human activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer.
Singh, J., Fattah, F., Burks, T., Zheng, J., Jiang, X., Kurian, P., … Khan, S. A. (2017). In-human activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
Tawfik, B., Gerber, D. E., Burtness, B., Hughes, R. S., Myers, L. L., Sumer, B. D., … Khan, S. A. (2017). Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus
Arora, N., Gupta, A., Zhu, H., Christie, A., Meyer, J. J., Khan, S. A., & Beg, M. S. (2017). Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(8), 998–1004. -
Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer
Goel, R., Moore, W., Sumer, B., Khan, S., Sher, D., & Subramaniam, R. M. (2017). Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 209(2), 289–303. -
Prevalence of autoimmune conditions among patients with lung cancer: Implications for immunotherapy treatment options.
Khan, S. A., Xuan, L., Pruitt, S., & Gerber, D. E. (2016). Prevalence of autoimmune conditions among patients with lung cancer: Implications for immunotherapy treatment options. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
Bhatia, A. K., Mehra, R., Khan, S. A., Egleston, B. L., Alpaugh, R. K., Lango, M., … Burtness, B. (2016). Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab
Brown, T. J., Sher, D. J., Nedzi, L. A., Hughes, R. S., Beg, M. S., Mull, J., … Khan, S. A. (2017). Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 39(5), E69–E71. -
Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions
Vanden Borre, P., Schrock, A. B., Anderson, P. M., Morris, J. C., Heilmann, A. M., Holmes, O., … Ali, S. M. (2017). Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. ONCOLOGIST, 22(3), 255–263. -
A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck
Chun, S. G., Hughes, R., Sumer, B. D., Myers, L. L., Truelson, J. M., Khan, S. A., … Nedzi, L. A. (2017). A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck. CANCER INVESTIGATION, 35(1), 23–31. -
National Patterns of Care and Predictors of Neoadjuvant and Concurrent Chemotherapy Use With Definitive Radiotherapy in the Treatment of Patients With Oropharyngeal Squamous Cell Carcinoma
Sher, D. J., Rusthoven, C. G., Khan, S. A., Fidler, M. J., Zhu, H., & Koshy, M. (2017). National Patterns of Care and Predictors of Neoadjuvant and Concurrent Chemotherapy Use With Definitive Radiotherapy in the Treatment of Patients With Oropharyngeal Squamous Cell Carcinoma. CANCER, 123(2), 273–282. -
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options
Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016). Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. JAMA ONCOLOGY, 2(11), 1507–1508. -
Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit
Cabanillas, M. E., Busaidy, N. L., Khan, S. A., Gunn, G. B., Dadu, R., Rao, S. N., & Waguespack, S. G. (2016). Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 3(3), 221–233. -
Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
Khan, S. A., Ci, B., Gerber, D. E., McFadden, D. G., Beg, M. S., Xie, Y., … Ali, S. M. (2016). Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era
Sher, D. J., Nedzi, L., Khan, S., Hughes, R., Sumer, B. D., Myers, L. L., … Koshy, M. (2016). Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 142(8), 777–788. -
Racial and sex disparities in changing trends of squamous cell cancer of the anus (SSCA).
Gupta, A., Zhu, H., Christie, A., Meyer, J. J., Khan, S. A., & Beg, M. S. (2016). Racial and sex disparities in changing trends of squamous cell cancer of the anus (SSCA). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers
Jean, G. W., Mani, R. M., Jaffry, A., & Khan, S. A. (2016). Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. JAMA ONCOLOGY, 2(4), 529–534. -
Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis
Sher, D. J., Schwartz, D. L., Nedzi, L., Khan, S., Hughes, R., Fidler, M. J., & Koshy, M. (2016). Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis. ORAL ONCOLOGY, 54, 58–67. -
Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma
Heilmann, A., Subbiah, V., Wang, K., Elvin, J., Chmielecki, J., Yelensky, R., … Stephens, P. (2015). Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Patterns of distant metastases in HPV-positive head and neck squamous cell carcinoma.
Law, J. Y., Chen, S. A., Gerber, D. E., Hughes, R. S., Madrigales, A., Myers, L. L., … Khan, S. A. (2014). Patterns of distant metastases in HPV-positive head and neck squamous cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities.
Khan, S. A., Bauman, J. E., Burtness, B., Frankel, A. E., Harper, J., Hughes, R. S., … Zhu, H. (2015). Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Neuroendocrine tumors of the head and neck: SEER analysis of survival and incidence.
Khan, S. A., Zhu, H., & Bacalao, M. (2015). Neuroendocrine tumors of the head and neck: SEER analysis of survival and incidence. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
Owonikoko, T. K., Dahlberg, S. E., Khan, S. A., Gerber, D. E., Dowell, J., Moss, R. A., … Ramalingam, S. S. (2015). A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). LUNG CANCER, 89(1), 66–70. -
Use of 18-FDG PET in Determination of Disease Extent in HPV/p16-Positive Oropharyngeal Squamous Cell Carcinoma
Gannavarapu, B., Sumer, B. D., Prabhu, R. S., Yordy, J. S., Nedzi, L. A., Khan, S. A., … Chen, S. A. (2014). Use of 18-FDG PET in Determination of Disease Extent in HPV/p16-Positive Oropharyngeal Squamous Cell Carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
McLean, L. S., Morris, T. A., Gramza, A., Liu, S., Khan, S. A., Colevas, A. D., … Rischin, D. (2022). A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. Investigational New Drugs. -
Abemaciclib in metastatic or locally advanced anaplastic thyroid cancer.
Khanna, V., Miles, C., Sundaram, V., Sheth, S., Steffen, M., Biedermann, S., … Khan, S. A. (2022). Abemaciclib in metastatic or locally advanced anaplastic thyroid cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.
Sherman, E. J., Harris, J., Bible, K. C., Xia, P., Ghossein, R. A., Chung, C. H., … Lee, N. Y. (2023). Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. The Lancet. Oncology. -
AMADEUS TRIAL: TUMOR AGNOSTIC PRE- AND ONTREATMENT BIOMARKERS OF RESPONSE TO NIVOLUMAB PLUS IPILIMUMAB CORRELATE WITH ONTREATMENT TUMORAL T CELL INFILTRATION
Alayli, F., Okrah, K., Tsimberidou, A., Drakaki, A., Khalil, D., Khan, S., … Sharma, P. (2022). AMADEUS TRIAL: TUMOR AGNOSTIC PRE- AND ONTREATMENT BIOMARKERS OF RESPONSE TO NIVOLUMAB PLUS IPILIMUMAB CORRELATE WITH ONTREATMENT TUMORAL T CELL INFILTRATION. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
Colevas, A. D. D., Rudek, M. A., Even, C., Lee, V. H.-F., Gillison, M. L., Khan, S. A., … Messick, T. (2023). Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Opioid prescribing patterns for head and neck cancer radiation patients, with a comparison to breast cancer radiation patients
Lasonde, B., Lu, R., Hawa, S., Biedermann, S., Lai, S., Winters, E., & Khan, S. A. (2023). Opioid prescribing patterns for head and neck cancer radiation patients, with a comparison to breast cancer radiation patients. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
-
Survivin expression and impact on head and neck cancer outcomes.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
- Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
- Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
- Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
- An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
- A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Practice Locations
Head and Neck Cancer Program at 900 Blake Wilbur Palo Alto, CA
Palo Alto, CA
Head and Neck Cancer Program at 900 Blake Wilbur
900 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereEndocrine Tumor Program - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Endocrine Tumor Program - 900 Blake Wilbur Drive
900 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(53 reviews)
Thorough, competent and caring.
I am very grateful for the help and care that Dr. Khan gives me.
Dr Saad Khan is easy to understand and was happy to answer my questions. I appreciate his kindness when talking to me.
He really makes it easy for me to understand. I appreciate his demeanor and gracious attitude . Thank you Dr Kahn
Very understanding on his professionalism to handle this issue with me.
Great job Doc.
Dr. Khan communicates well with the patient. This contributes to the confidence that the patient develops for Dr. Khan. He answers all questions in a calm, straight-forward manner without rushing. His credentials and position of responsibility in the Oncology dept are impressive. He uses test results to come to conclusions vs. relying on personal opinion.
Dr Khan was very good at explaining the treatment options
For once i felt this appointment was all about me, i loved how when i left this appointment i didnt feel confused all my questions and concerns were answered
Dr. Kahn is PRO !
Thanks for getting me in so soon.
Dr Khan is extremely considerate and caring about patient care and well being. I feel very comfortable with his decisions.
Thank you for your help with my health issues.
Dr. Khan is very compassionate and thorough with my health condition.
Very informative, answered all of my questions
The care that I have received from all the people at Stanford has been second to none. I will always recommend people go there for their care.
He's a good doctor and all-around good guy.
The care providers that I have been with at Stanford have ALL been special and excellent people, however the car parking situation is atrocious.
I am currently receiving chemotherapy under Dr. Kahns care. I know that I'm receiving the best care possible.
No wait, good discussion with MD.
Seemed caring and friendly
Thanks for your patience fine tuning answers for me when we're dealing with a certain amount of nuance about my "developing" status.
Excellent thorough doctor.
Dr. Khan is always very upbeat and I enjoy working with him and his team with my care.
Great upbeat attitude
Dr Khan is fantastic. He listens, answers all my questions, and treats a ne with kindness and respect. He’s smart, knowledgeable and current on my chart.
Dr. Khan and his team are great!
Dr Kahn listens and his support team are amazing!
DrKahn and his team are very professional, courteous and confidence inspiring. I agree with everything we talked about but am still unconvinced that all aspects of my future treatment need to be moved from the very competent and supportive local team which have so far solved my problems and been locally available and supportive to Stanford 2 hours hard travel away. In the past 3 days I have received numerous contacts attempting to establish future appointments while I have not yet discussed this with my existing oncologist. Feels a little pushy for a patient in remission
I have been very satisfied with my visits with Dr. Khan.
ALL staff from radiology to Dr Kahn was A one!
Very good
Excellent communicator as well structuring cancer care that worked out well for me
excellent care and information
I find him to be considerate, compassionate and very knowledgeable. He is willing to listen to the patient's concerns and answer questions in a dialogue of "give and take."
He is good.
I appreciate Dr. Kahn’s, “down to earth†approach to discussing my concerns and listening to my view during our meetings.
The Dr Kahn was very informative and answered all the questions we had. His information was very helpful and easy to understand. I wish my Oncologist at Kaiser was better at communication.
All was good
Dr Khan is knowledgeable, empathtic, and really listened to my concerns.
The best
Dr Kahn explained things very clearly and completely. He answered all questions. I'm very happy with Dr. Khan.
A good consultation
I appreciate Dr. Khan’s manner of communication and his way of explaining the situation that we are dealing with. He is definitely willing to listen to me and hear my point of view.
Dr. Khan is the best. He truly cares about his patients. He is straightforward and give you factual information.
I really enjoyed meeting with Dr. Khan. Unfortunately I will not be able to remain under his care for my treatment but he has assured me that’s the South Bay center will provide good care.
he is the best
Good!
EXCELLENT
Very well spoken, courteous, informative, gave time for my questions. Really appreciated him.
Friendly, personable, relaxed and confident, just what I need in a doctor!
Dr. Khan is knowledgeable, sensitive, personable, clear-spoken doc. We talked easily and well and to good effect.
This was my first visit with Dr Khan. He is fantastic. I’m thrilled he’ll be overseeing my care. I feel like I am in excellent hands. It’s a huge relief. He listened to and answered all of my questions and concerns.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records